Processing. Please wait.



Huw Jones

Chronos Therapeutics

About Huw

Huw has been CEO of Chronos Therapeutics in Oxford since 2013.

In that time he has extracted the company from Oxford University, raised substantial grant and equity finance and led Chronos’ acquisition of three early research programmes in brain disease from Shire PLC.

He was surprised and pleased to have been awarded European CEO of the year 2016 for drug discovery by European CEO
Magazine, alongside leaders in their sectors from Adidas, Unilever and Spotify.

Previous posts include: NED, then rescue CEO, Ardana PLC; non–executive chairman, Ashbourne Pharmaceuticals; president Europe, CV Therapeutics Inc; SVP, Elan Pharmaceuticals and various roles of increasing responsibility at SmithKline Beecham (GSK).

In his varied career he has launched dozens of new medicines in several countries, completed tens of M&A transactions and managed many drug development programmes. Huw holds a PhD in neuropharmacology from the University of Birmingham, he is a passionate SCUBA diver and wine lover but never combines the two.

Speaker's Sessions:

1570789800 - 1570792500
Elgar Concert Hall

Panel: Going to America?

The US Healthcare market is valued at more than $2.8 Trillion and is frequently the number one priority for UK / Europe life sciences companies looking to expand their international presence and set up foreign subsidiaries. A US presence also facilitates the access to the US investment and capital markets, and the downstream opportunity to IPO via the Nasdaq equity market.

Whilst there are many similarities in business approach and language, there are also significant cultural and legal differences which can catch out the unwary when seeking to establish and operate a local entity.
Expanding into new markets, geographies, and market segments can be immensely rewarding but also challenging if approached without adequate preparation, knowledge and support. Companies need to think strategically about which avenues they need to explore to develop realistic market access strategies that create the opportunity for growth and long-term value creation.

Our expert panel will provide well informed advice as to how best to approach establishing a North American entity and develop practical strategies and plans to optimise operations, organisational structures, financials and processes across the life sciences value chain to maximise their chances of business success in this dynamic healthcare market.

Our panel will offer advice on the following topics:

  • East, West, or Middle – are there areas more suitable for R&D or manufacturing operations?
  • Impact of time zones, access and travel
  • What are the varying incentives and taxation differences between States
  • FDA clearance and approval to obtain FDA certification
  • Risk management and insurance provisions to consider
  • Incorporation or branch legal structure?
  • Visas, relocation, tax, immigration issues
  • Differences in IP between the UK and US e.g. first to file vs first to invent
  • Understanding how the health system works
  • Access to investment, capital, grants and where to leverage practical setup support
  • Tips on recruiting & retaining local staff
  • Identifying and interacting with a new range of US out-source partners
  • Local networking and interaction with the community